Danaher completes acquisition of Masimo Corporation
Masimo becomes a wholly-owned subsidiary, operating under its brand within Danaher's Diagnostics segment, strengthening acute care diagnostics with pulse oximetry and AI monitoring.
See the latest news and media coverage for Danaher. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life sciences and diagnostics innovator
danaher.comLast updated
In short: Danaher completed its $9.9 billion acquisition of Masimo Corporation and reported strong Q1 2026 financial results that exceeded market estimates.
Masimo becomes a wholly-owned subsidiary, operating under its brand within Danaher's Diagnostics segment, strengthening acute care diagnostics with pulse oximetry and AI monitoring.
It will raise about €2.98 billion to help fund the Masimo acquisition and for general corporate purposes. The offering is expected to close on 2026-04-29.
Net earnings reach $1.0B, revenues grow 3.5% to $6.0B, adjusted EPS up 9.5%. Announces intent to acquire Masimo. Raises full-year guidance.
Beckman Coulter Diagnostics gains CE Mark for Access MeMed BV assay to differentiate infections in 20 minutes. Cepheid expands partnership with Oxford Nanopore for genomic workflows.
Madison Investments, an investment advisor, released its first-quarter 2026 investor letter for the “Madison Large Cap Fund”.
The Danaher company expands its collaboration with AstraZeneca and Daiichi Sankyo to develop an end-to-end system for TROP2 NMR in non-small cell lung cancer...
Danaher is seeing strong Biotechnology growth as bioprocessing demand rises, with equipment orders...
On June 11, 2026, Piper Sandler initiated coverage on Danaher Corp (DHR) with a Neutral rating,...
Track Danaher and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Danaher and other trending companies.